{"id":15612,"date":"2023-08-01T02:06:00","date_gmt":"2023-07-31T18:06:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15612"},"modified":"2024-11-29T02:09:43","modified_gmt":"2024-11-28T18:09:43","slug":"viatris-inc-secures-fda-nod-for-generic-symbicort-equivalent-breyna","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15612","title":{"rendered":"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna"},"content":{"rendered":"\n

US-based Viatris Inc., (NASDAQ: VTRS<\/a>) has announced that the US Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for Breyna (budesonide + formoterol fumarate dihydrate), a generic version of AstraZeneca’s originator product Symbicort. This approval positions Viatris as the first company to offer an FDA-approved generic alternative to Symbicort, expanding treatment options for patients with asthma or chronic obstructive pulmonary disease (COPD).<\/p>\n\n\n\n

Breyna’s Indications and Partnership<\/strong>
Breyna, developed in partnership with Kindeva Drug Delivery LP, is a drug and device combination product indicated for use in treating patients with asthma or COPD. It is available in two dosage forms: 80mcg\/4.5mcg and 160mcg\/4.5mcg. The product can be used to treat asthma in patients aged six years or older and as a maintenance treatment for airflow obstruction and reducing exacerbations in patients with COPD, including chronic bronchitis and\/or emphysema. It is important to note that Breyna is not intended for the relief of acute bronchospasm, with the 160 mcg\/4.5 mcg form specifically for COPD treatment.<\/p>\n\n\n\n

Market Potential and AstraZeneca’s Sales Performance<\/strong>
The market potential for Symbicort is substantial, with an estimated 16 million COPD sufferers and 15 million chronic asthma sufferers in the United States. AstraZeneca reported global sales revenues of USD 1.28 billion for Symbicort during the first half of 2023, demonstrating a 4% year-on-year growth, indicating a strong demand for this class of respiratory medications.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA)…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[31,15,207],"class_list":["post-15612","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-generic-drugs","tag-product-approvals","tag-viatris"],"yoast_head":"\nViatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Breyna (budesonide + formoterol fumarate dihydrate), a generic version of AstraZeneca's originator product Symbicort. This approval positions Viatris as the first company to offer an FDA-approved generic alternative to Symbicort, expanding treatment options for patients with asthma or chronic obstructive pulmonary disease (COPD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15612\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15612\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-31T18:06:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-28T18:09:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15612#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15612\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna\",\"datePublished\":\"2023-07-31T18:06:00+00:00\",\"dateModified\":\"2024-11-28T18:09:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15612\"},\"wordCount\":245,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Generic drugs\",\"Product approvals\",\"Viatris\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15612#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15612\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15612\",\"name\":\"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-31T18:06:00+00:00\",\"dateModified\":\"2024-11-28T18:09:43+00:00\",\"description\":\"US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Breyna (budesonide + formoterol fumarate dihydrate), a generic version of AstraZeneca's originator product Symbicort. This approval positions Viatris as the first company to offer an FDA-approved generic alternative to Symbicort, expanding treatment options for patients with asthma or chronic obstructive pulmonary disease (COPD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15612#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15612\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15612#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna - Insight, China's Pharmaceutical Industry","description":"US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Breyna (budesonide + formoterol fumarate dihydrate), a generic version of AstraZeneca's originator product Symbicort. This approval positions Viatris as the first company to offer an FDA-approved generic alternative to Symbicort, expanding treatment options for patients with asthma or chronic obstructive pulmonary disease (COPD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15612","og_locale":"en_US","og_type":"article","og_title":"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15612","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-31T18:06:00+00:00","article_modified_time":"2024-11-28T18:09:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15612#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15612"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna","datePublished":"2023-07-31T18:06:00+00:00","dateModified":"2024-11-28T18:09:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15612"},"wordCount":245,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Generic drugs","Product approvals","Viatris"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15612#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15612","url":"https:\/\/flcube.com\/?p=15612","name":"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-31T18:06:00+00:00","dateModified":"2024-11-28T18:09:43+00:00","description":"US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Breyna (budesonide + formoterol fumarate dihydrate), a generic version of AstraZeneca's originator product Symbicort. This approval positions Viatris as the first company to offer an FDA-approved generic alternative to Symbicort, expanding treatment options for patients with asthma or chronic obstructive pulmonary disease (COPD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15612#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15612"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15612#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15612"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15612\/revisions"}],"predecessor-version":[{"id":15613,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15612\/revisions\/15613"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}